Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Staskin

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
Reviews in Urology|January 31, 2008
Anticholinergics and central nervous system effects: are we confused?David R Staskin, Edward Zoltan
Current Urology Reports|October 22, 2005
The Q-T interval and antimuscarinic drugsRoger Dmochowski, David R Staskin
Current Urology Reports|October 22, 2005
Mixed incontinence: the misclassification of patients and limitations of clinical trialsRenuka Tyagi, David R Staskin
Current Urology Reports|November 19, 2003
Nocturia: when is it not related to overactive bladder?Konstantin Walmsley, David R Staskin
Expert Opinion on Pharmacotherapy|December 4, 2009
Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladderDavid R Staskin, Dudley Robinson
Current Urology Reports|October 2, 2002
Synthetic slings: pros and consDavid R Staskin, Louis Plzak
Current Urology Reports|September 23, 2003
Artificial graft slings at the midurethra: physiology of continenceJennifer Tash, David R Staskin
Current Medical Research and Opinion|June 23, 2005
Is it possible to make cross-study comparisons of urinary continence rates in patients with overactive bladder?David R Staskin, Alan Wein
Urology|December 21, 2002
Future studies of overactive bladder: the need for standardizationDavid R Staskin, Roger R Dmochowski
European Urology|October 3, 2008
Re: Christopher R. Chapple, Vik Khullar, Zahava Gabriel, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543-62David R Staskin, Michael G Oefelein
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
Reviews in Urology|January 31, 2008
Anticholinergics and central nervous system effects: are we confused?David R Staskin, Edward Zoltan
Current Urology Reports|October 22, 2005
The Q-T interval and antimuscarinic drugsRoger Dmochowski, David R Staskin
Current Urology Reports|October 22, 2005
Mixed incontinence: the misclassification of patients and limitations of clinical trialsRenuka Tyagi, David R Staskin
Current Urology Reports|November 19, 2003
Nocturia: when is it not related to overactive bladder?Konstantin Walmsley, David R Staskin
Expert Opinion on Pharmacotherapy|December 4, 2009
Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladderDavid R Staskin, Dudley Robinson
Current Urology Reports|October 2, 2002
Synthetic slings: pros and consDavid R Staskin, Louis Plzak
Current Urology Reports|September 23, 2003
Artificial graft slings at the midurethra: physiology of continenceJennifer Tash, David R Staskin
Current Medical Research and Opinion|June 23, 2005
Is it possible to make cross-study comparisons of urinary continence rates in patients with overactive bladder?David R Staskin, Alan Wein
Urology|December 21, 2002
Future studies of overactive bladder: the need for standardizationDavid R Staskin, Roger R Dmochowski
European Urology|October 3, 2008
Re: Christopher R. Chapple, Vik Khullar, Zahava Gabriel, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543-62David R Staskin, Michael G Oefelein
Pageof 6